164062-69-5 Usage
General Description
2-(4-ethyl-phenyl)-1H-imidazole is a chemical compound that belongs to the class of imidazole derivatives. It is derived from imidazole, a five-membered heterocyclic ring containing two nitrogen atoms. The compound contains a phenyl ring with an ethyl group attached to the fourth position, giving it its specific structure. Imidazoles have diverse biological activities and are utilized in the synthesis of various pharmaceuticals and agrochemicals. This chemical may have potential applications in medicinal chemistry, including as a starting material for the synthesis of bioactive compounds or as a ligand in coordination chemistry. As imidazoles are known to be important building blocks in organic synthesis, 2-(4-ethyl-phenyl)-1H-imidazole could be utilized in the development of new molecules with potential therapeutic properties.
Check Digit Verification of cas no
The CAS Registry Mumber 164062-69-5 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,6,4,0,6 and 2 respectively; the second part has 2 digits, 6 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 164062-69:
(8*1)+(7*6)+(6*4)+(5*0)+(4*6)+(3*2)+(2*6)+(1*9)=125
125 % 10 = 5
So 164062-69-5 is a valid CAS Registry Number.
164062-69-5Relevant articles and documents
Discovery of 4-aryl-2-benzoyl-imidazoles as tubulin polymerization inhibitor with potent antiproliferative properties
Xiao, Min,Ahn, Sunjoo,Wang, Jin,Chen, Jianjun,Miller, Duane. D.,Dalton, James T,Li, Wei
, p. 3318 - 3329 (2013/06/26)
A series of 4-aryl-2-benzoyl-imidazoles were designed and synthesized based on our previously reported 2-aryl-4-benzoyl-imidazole (ABI) derivatives. The new structures reversed the aryl group and the benzoyl group of previous ABI structures and were named as reverse ABI (RABI) analogues. RABIs were evaluated for biological activity against eight cancer cell lines including multidrug-resistant cancer cell lines. In vitro assays indicated that several RABI compounds had excellent antiproliferative properties, with IC50 values in the low nanomolar range. The average IC50 of the most active compound 12a is 14 nM. In addition, the mechanism of action of these new analogues was investigated by cell cycle analysis, tubulin polymerization assay, competitive mass spectrometry binding assay, and molecular docking studies. These studies confirmed that these new RABI analogues maintain their mechanisms of action by disrupting tubulin polymerization, similar to their parental ABI analogues.
